As a result of intensive selection in cultivation, Cannabis exhibits many sexual phenotypes that can be described in terms of the ratio of female to male flowers occurring in the individual, or typical in the cultivar. Dioecious varieties are preferred for drug production, where the female flowers are used. Dioecious varieties are also preferred for textile fiber production, whereas monoecious varieties are preferred for pulp and paper production. It has been suggested that the presence of monoecy can be used to differentiate licit crops of monoecious hemp from illicit drug crops. However, sativa strains often produce monoecious individuals, probably as a result of inbreeding.
With marijuana, apparently, we’re still waiting for this information. It’s hard to study a substance that until very recently has been almost universally illegal. And the few studies we do have were done mostly in the nineteen-eighties and nineties, when cannabis was not nearly as potent as it is now. Because of recent developments in plant breeding and growing techniques, the typical concentration of THC, the psychoactive ingredient in marijuana, has gone from the low single digits to more than twenty per cent—from a swig of near-beer to a tequila shot.
In fact, many kinds of pains related to specific systems of the body can be managed more effectively through the use of cannabidiol oil. Many use CBD oil for muscle pain, but CBD oil for nerve pain is just as effective. What has been discovered is that the effectiveness of CBD oil for neuropathic pain in general is what is making this such a wonder remedy for so many different kinds of issues related to pain.
In a July 1998 study issued by the Center for Business and Economic Research at the University of Kentucky, researchers concluded that Kentucky hemp farmers could earn a net profit of $600 per acre for raising certified seeds, $320 net profit per acre for straw only or straw and grain production, and $220 net profit per acre for grain only production. The only crop found to be more profitable was tobacco.
There are many varieties of cannabis infusions owing to the variety of non-volatile solvents used. The plant material is mixed with the solvent and then pressed and filtered to express the oils of the plant into the solvent. Examples of solvents used in this process are cocoa butter, dairy butter, cooking oil, glycerine, and skin moisturizers. Depending on the solvent, these may be used in cannabis foods or applied topically.
One claim is that Hearst believed[dubious – discuss] that his extensive timber holdings were threatened by the invention of the decorticator which he feared would allow hemp to become a cheap substitute for the paper pulp used for newspaper. Historical research indicates this fear was unfounded because improvements of the decorticators in the 1930s – machines that separated the fibers from the hemp stem – could not make hemp fiber a cheaper substitute for fibers from other sources. Further, decorticators did not perform satisfactorily in commercial production.
Some individuals have been found to have mutations on the CNR1 gene, which is responsible for coding the CB1 receptor (a type of receptor in cells throughout your body that interacts with cannabinoids). Issues with the CNR1 gene can ultimately result in a poorly functioning endocannabinoid system, which is an important variable when figuring out how to use CBD oil.
I have read about studies from Europe (not very specific I know) that suggest CBD might work better for some people if combined with some level of THC. Also, the getting high part can be helpful, although not for everybody, of course. A second point – I don’t hear very much about CBD eliminating or almost eliminating pain for people with severe pain. Helpful, but, so far at least, it doesn’t seem that CBDs can replace opioids or substantially reduce pain for all chronic pain patients. Maybe someday.
"Results of the hemp products tested indicate the amount of THC present in commercially available products is significantly less in products available today than those reported in the past (15-22). As a result, the probability that these products will produce urine THC metabolite levels greater than the DoD and HHS confirmation cutoff of 15 ng/mL is significantly reduced and should not be considered as a realistic cause for a positive urine analysis result."
^ Juliet Eilperin (February 11, 2013), "'Good seed' versus 'evil weed': Hemp activists eye legalization", The Washington Post – via The Japan Times Online, [A] couple of factors — the high taxes the federal government imposed on growing hemp in the late 1930s and again in the early '50s, and then the DEA's interpretation of the 1970 law — made producing hemp nearly impossible. Since the DEA only grants permits in rare instances and demands costly, elaborate security precautions, large-scale hemp growing in the United States is not viable.
Both in Canada and the US, the most critical problem to be addressed for commercial exploitation of C. sativa is the possible unauthorized drug use of the plant. Indeed, the reason hemp cultivation was made illegal in North America was concern that the hemp crop was a drug menace. The drug potential is, for practical purposes, measured by the presence of THC. THC is the world’s most popular illicit chemical, and indeed the fourth most popular recreational drug, after caffeine, alcohol, and nicotine. “Industrial hemp” is a phrase that has become common to designate hemp used for commercial non-intoxicant purposes. Small and Cronquist (1976) split C. sativa into two subspecies: C. sativa subsp. sativa, with less than 0.3% (dry weight) of THC in the upper (reproductive) part of the plant, and C. sativa subsp. indica (Lam.) E. Small & Cronq. with more than 0.3% THC. This classification has since been adopted in the European Community, Canada, and parts of Australia as a dividing line between cultivars that can be legally cultivated under license and forms that are considered to have too high a drug potential. For a period, 0.3% was also the allowable THC content limit for cultivation of hemp in the Soviet Union. In the US, Drug Enforcement Agency guidelines issued Dec. 7, 1999 expressly allowed products with a THC content of less than 0.3% to enter the US without a license; but subsequently permissible levels have been a source of continuing contention. Marijuana in the illicit market typically has a THC content of 5% to 10% (levels as high as 25% have been reported), and as a point of interest, a current Canadian government experimental medicinal marijuana production contract calls for the production of 6% marijuana. As noted above, a level of about 1% THC is considered the threshold for marijuana to have intoxicating potential, so the 0.3% level is conservative, and some countries (e.g. parts of Australia, Switzerland) have permitted the cultivation of cultivars with higher levels. It should be appreciated that there is considerable variation in THC content in different parts of the plant. THC content increases in the following order: achenes (excluding bracts), roots, large stems, smaller stems, older and larger leaves, younger and smaller leaves, flowers, perigonal bracts covering both the female flowers and fruits. It is well known in the illicit trade how to screen off the more potent fractions of the plant in order to increase THC levels in resultant drug products. Nevertheless, a level of 0.3% THC in the flowering parts of the plant is reflective of material that is too low in intoxicant potential to actually be used practically for illicit production of marijuana or other types of cannabis drugs. Below, the problem of permissible levels of THC in food products made from hempseed is discussed.
"Federal law prohibits cultivation without a permit. DEA determines whether any industrial hemp production authorized under a state statute is permitted, and it enforces standards governing the security conditions under which the crop must be grown. In other words, a grower needs to get permission from DEA to grow hemp or faces the possibility of federal charges or property confiscation, regardless of whether the grower has a state-issued permit.61
The 2018 Farm Bill changed federal policy regarding industry hemp, including the removal of hemp from the Controlled Substances Act and the consideration of hemp as an agricultural product. The bill legalized hemp under certain restrictions and expanded the definition of industrial hemp from the last 2014 Farm Bill. The bill also allows states and tribes to submit a plan and apply for primary regulatory authority over the production of hemp in their state or in their tribal territory. A state plan must include certain requirements, such as keeping track of land, testing methods, and disposal of plants or products that exceed the allowed THC concentration.
Due to almost a century of misinformation about Cannabis, the distinction between Cannabis and its two primary species — hemp and marijuana — has become unclear to the many and some even consider the three plants to be one in the same. Because of this, the three terms are often used interchangeably, which has created difficulties when understanding the usage and benefits of Hemp vs Marijuana and Cannabis in general.
Smaller companies focused on CBD beverages, such as New Age Beverages Corp. NBEV, -1.47% , have been targeted by investors, but some firms have used CBD-related announcements to pump stock prices as well as fuel excitement in a compound that scientists do not fully understand. Other companies operating in the sector will benefit too: Charlotte’s Web Holdings Inc. CWBHF, +5.11% has focused on a range of CBD products, capturing about 17% market share in 2017 with sales in 3,000 retail locations, according to PI Financial research.
In June 2018, the FDA approved the drug Epidiolex, an oral preparation of pure CBD for treatment of two rare and severe forms of epilepsy in children. The drug is made by the GW Pharmaceutical Company and was tested in three randomized, double-blind, placebo-controlled clinical trials, including 516 patients. It was found to be effective in reducing the frequency of seizures.
Despite the fact that Cannabis was grown on a large scale in many countries, the abuse as a narcotic remained uncommon in Western countries until relatively recently. People were largely unaware of the psychoactive properties of Cannabis and it is unlikely that early cultivars, selected mainly for their seed or fiber qualities, contained significant amounts of the psychoactive THC. The medicinal use of Cannabis was introduced in Europe only around 1840, by a young Irish doctor, William O’Shaughnessy, who served for the East India Trading Company in India, where the medicinal use of Cannabis was widespread. Unlike the European fiber Cannabis, these Indian varieties did contain a reasonable amount of bioactive cannabinoids. In the following decades, the medicinal use of Cannabis saw a short period of popularity both in Europe and in the United States. At the top of its popularity, more than 28 different medicinal preparations were available with Cannabis as active ingredient, which were recommended for indications as various as menstrual cramps, asthma, cough, insomnia, support of birth labor, migraine, throat infection, and withdrawal from opium use.27
Marijuana has in fact been grown for medicinal research in North America by both the Canadian (Fig. 40) and American governments, and this will likely continue. The possibility of marijuana becoming a legal commercial crop in North America is, to say the least, unlikely in the foreseeable future. Nevertheless the private sector is currently producing medicinal marijuana in Europe and Canada, so the following orientation to marijuana as a potential authorized crop is not merely academic.
“What we know is that THC and CBD combined has a greater therapeutic effect than either one given alone,” Lee continued. “The best medicines to use are the medicines that have both THC and CBD. What we suggest to people – and I will emphasize we are not doctors – is that people should use products that have as much THC as possible, with the CBD, that doesn’t make them feel dysphoric or stoned.”
“Geotextiles” or “agricultural textiles” include (1) ground-retaining, biodegradable matting designed to prevent soil erosion, especially to stabilize new plantings while they develop root systems along steep highway banks to prevent soil slippage (Fig. 32); and (2) ground-covers designed to reduce weeds in planting beds (in the manner of plastic mulch). At present the main materials used are polymeric (polythene, spun-blown polypropylene) and some glass fiber and natural fibers. Both woven and non-woven fibers can be applied to geotextiles; woven and knitted materials are stronger and the open structure may be advantageous (e.g. in allowing plants to grow through), but non-wovens are cheaper and better at suppressing weeds. Flax and hemp fibers exposed to water and soil have been claimed to disintegrate rapidly over the course of a few months, which would make them unacceptable for products that need to have long-term stability when exposed to water and oil. Coco (coir) fiber has been said to be much more suitable, due to higher lignin content (40%–50%, compared to 2%–5% in bast fibers); these are much cheaper than flax and hemp fibers (Karus et al. 2000). However, this analysis does not do justice to the developing hemp geotextile market. Production of hemp erosion control mats is continuing in both Europe and Canada. Given the reputation for rot resistance of hemp canvas and rope, it seems probable that ground matting is a legitimate use. Moreover, the ability to last outdoors for many years is frequently undesirable in geotextiles. For example, the widespread current use of plastic netting to reinforce grass sod is quite objectionable, the plastic persisting for many years and interfering with lawn care. Related to geotextile applications is the possibility of using hemp fiber as a planting substrate (biodegradable pots and blocks for plants), and as biodegradable twine to replace plastic ties used to attach plants to supporting poles. Still another consideration is the “green ideal” of producing locally for local needs; by this credo, hemp is preferable in temperate regions to the use of tropical fibers, which need to be imported.
The world-leading producer of hemp is China, which produces more than 70% of the world output. France ranks second with about a quarter of the world production. Smaller production occurs in the rest of Europe, Chile, and North Korea. Over 30 countries produce industrial hemp, including Australia, Austria, Canada, Chile, China, Denmark, Egypt, Finland, Germany, Greece, Hungary, India, Italy, Japan, Korea, Netherlands, New Zealand, Poland, Portugal, Romania, Russia, Slovenia, Spain, Sweden, Switzerland, Thailand, Turkey, the United Kingdom and Ukraine.
This article reviews recent research on cannabinoid analgesia via the endocannabinoid system and non-receptor mechanisms, as well as randomized clinical trials employing cannabinoids in pain treatment. Tetrahydrocannabinol (THC, Marinol®) and nabilone (Cesamet®) are currently approved in the United States and other countries, but not for pain indications. Other synthetic cannabinoids, such as ajulemic acid, are in development. Crude herbal cannabis remains illegal in most jurisdictions but is also under investigation. Sativex®, a cannabis derived oromucosal spray containing equal proportions of THC (partial CB1 receptor agonist ) and cannabidiol (CBD, a non-euphoriant, anti-inflammatory analgesic with CB1 receptor antagonist and endocannabinoid modulating effects) was approved in Canada in 2005 for treatment of central neuropathic pain in multiple sclerosis, and in 2007 for intractable cancer pain. Numerous randomized clinical trials have demonstrated safety and efficacy for Sativex in central and peripheral neuropathic pain, rheumatoid arthritis and cancer pain. An Investigational New Drug application to conduct advanced clinical trials for cancer pain was approved by the US FDA in January 2006. Cannabinoid analgesics have generally been well tolerated in clinical trials with acceptable adverse event profiles. Their adjunctive addition to the pharmacological armamentarium for treatment of pain shows great promise.
In the meantime, some physicians are forging ahead — and cashing in. Joe Cohen is a doctor at Holos Health, a medical marijuana clinic in Boulder. I asked him what CBD is good for, and he read me a long list of conditions: pain, inflammation, nausea, vomiting, intestinal cramping, anxiety, psychosis, muscle spasms, hyperactive immune systems, nervous system degeneration, elevated blood sugar and more. He also claimed that CBD has anti-cancer properties and can regenerate brain cells and reduce the brain’s levels of amyloid beta — a kind of protein that’s been linked to Alzheimer’s disease. I asked for references, noting that most of these weren’t listed in the Academies report or a similar review published in the Journal of the American Medical Association. “I think you just have to Google search it,” he said. It’s true that a preliminary study found hints that cannabinoids might reduce beta amyloid proteins in human brain cells, but the study was done in cells grown in a lab, not in people. As for cancer, the FDA sent warning letters last year to four companies that were selling products that claimed to “prevent, diagnose, treat or cure” cancer.
Medical marijuana refers to the use of the Cannabis plant as a physician-recommended herbal therapy as well as synthetic THC and cannabinoids. So far, the medical use of cannabis is legal only in a limited number of territories, including Canada, Belgium, Australia, the Netherlands, Spain, and many U.S. states. This usage generally requires a prescription, and distribution is usually done within a framework defined by local laws. There is evidence supporting the use of cannabis or its derivatives in the treatment of chemotherapy-induced nausea and vomiting, neuropathic pain, and multiple sclerosis. Lower levels of evidence support its use for AIDS wasting syndrome, epilepsy, rheumatoid arthritis, and glaucoma.
With so many companies popping up every day, we’ve done the hard work for you. We bring you the best CBD oil guide and the top 25 brands that made our list based on CBD oil quality, effectiveness, customer service and of course price. Please note, this article is updated constantly, so don’t forget come back from time to time to see the most updated information.
Hello. I have stage 4 thyroid, secondary lymphoma..And many other health issues.I use 50mg of cbd vapor oil. 5 drops with each use. Total equals 250mg, about hits per dose, three times a day. I'm also on subsys, which is fentanyl. Idk about anyone but myself, but it's helped me with pain, with sleep, and in general my moods. So I dint have anything negative to say. I just hope that with time, proper diet, low dose chemo, and some other herbal usage, that I can shirk some of the cancer eating at my body... Thanks and good luck to you all.
Researchers think that CBD interacts with receptors in your brain and immune system. Receptors are tiny proteins attached to your cells that receive chemical signals from different stimuli and help your cells respond. This creates anti-inflammatory and painkilling effects that help with pain management. This means that CBD oil may benefit people with chronic pain, such as chronic back pain.
Hemp is thus profitable and sustainable, two words which have eluded many U.S. farmers as of late. Hemp cultivation could provide much-needed relief as farmers struggle to find markets for millions of bushels of crops during the trade wars. Now, instead of importing an estimated $100 million of hemp products every year, that money will go to American farmers and entrepreneurs.
"No official estimates are available of the value of U.S. sales of hemp-based products. The Hemp Industries Association (HIA) reports total U.S. retail sales of hemp products of nearly $700 million in 2016,12 which includes food and body products, dietary supplements, clothing, auto parts, building materials, and other consumer products (Figure 2). HIA claims that U.S. hemp retail sales have increased by about 10% to more than 20% annually since 2011. Much of this growth is attributable to sales of hemp-based body products, supplements, and foods. Combined, these categories accounted for more than two-thirds of the value of U.S. retail sales in 2016.
CBC is another lesser-known yet still crucial cannabinoid in marijuana, especially from a therapeutic perspective. While bereft of the psychoactive quality of THC (and to a lesser extent THCV), CBC is gaining popularity as an anxiety reducer. While research on cannabichromene lags behind others, there’s good reason to continue looking into its potential as a medicine.
The US Drug Enforcement Administration’s online criminal justice statistics for 2000 (cscmosaic.albany.edu/sourcebook/1995/pdf/t440.pdf) shows the following seizures and eradication of plants of C. sativa: 40,929 outdoor plots (2,597,796 plants), 139,580,728 ditchweed (ruderal plants), 2,361 indoor operations (217,105 plants), for a grand total of 2,814, 903 plants destroyed. Impressively, the species was grown in all 50 states (including outdoor seizures in every state except Wyoming)! It is of course impossible to know exactly how much marijuana is cultivated in the United States, and perhaps only 10% to 20% of the amount grown is seized. The profitability of the illegal crop is indicated by a comparison of the cost of a bushel of corn (roughly $2.50) and a bushel of manicured marijuana (about $70,000; it has been suggested that prices range from $500 a pound, for low-quality marijuana, to more than $5,000 a pound for “boutique” strains like “Northern Lights” and “Afghan Kush”). According to a National Organization for the Reform of Marijuana Laws (NORML) (mir.drugtext.org/marijuananews/marijuana_ranks_fourth_largest_c.htm) marijuana is at least the fourth most valuable crop in America, outranked only by corn, soybeans, and hay. It was estimated that 8.7 million marijuana plants were harvested in 1997, worth $15.1 billion to growers and $25.2 billion on the retail market (the wholesale value was used to compare marijuana to other cash crops). Marijuana was judged to be the largest revenue producing crop in Alabama, California, Colorado, Hawaii, Kentucky, Maine, Rhode Island, Tennessee, Virginia, and West Virginia, and one of the top five cash crops in 29 other states.
First, you should not take anything without consulting your physician. While CBD oil is largely safe, a small number of people experience side effects and it could interact with medications you may already be taking like certain antidepressants and antibiotics. Do not be shy about discussing this option, the more open and honest you can be with your doctor, the more they can help you figure out the best path forward if you are considering using CBD oil for pain.
“We’re so pleased farmers across America now have the freedom to consider integrating this important crop into their production, particularly with the trade concerns around other crops such as soybeans, corn, and wheat," said Elizabeth Hogan, VP of Brands at GCH Inc., the company behind Willie Nelson’s cannabis brands. Hemp legalization will transform it from niche interest and return it to cash crop status.
The 2018 Farm Bill expands upon provisions in the 2014 version of the annual bill, which created Hemp Pilot Programs. These Hemp Pilot Programs “created a framework for the legal cultivation by states of ‘industrial hemp’ without a permit from the Drug Enforcement Administration.” The 2014 Hemp Pilot Programs were a success for farmers and consumers across the U.S., from Colorado to North Carolina.
There are practical, if cruder alternatives to separate the long fiber for high-quality textile production, but in fact such techniques are used mostly for non-textile applications. This involves production of “whole fibers” (i.e. harvesting both the long fibers from the cortex and the shorter fibers from throughout the stem), and technologies that utilize shortened hemp fibers. This approach is currently dominant in western Europe and Canada, and commences with field dew retting (typically 2–3 weeks). A principal limitation is climatic—the local environment should be suitably but not excessively moist at the close of the harvest season. Once stalks are retted, dried, and baled, they are processed to extract the fiber. In traditional hemp processing, the long fiber was separated from the internal woody hurds in two steps, breaking (stalks were crushed under rollers that broke the woody core into short pieces, some of which were separated) and scutching (the remaining hurds, short fibers (“tow”) and long fibers (“line fiber, ” “long-line fiber”) were separated). A single, relatively expensive machine called a decorticator can do these two steps as one. In general in the EU and Canada, fibers are not separated into tow and line fibers, but are left as “whole fiber.” In western Europe, the fiber is often “cottonized,” i.e. chopped into short segments the size of cotton and flax fiber, so that the fibers can be processed on flax processing machinery, which is very much better developed than such machinery is for hemp. In North America the use of hemp for production of even crude textiles is marginal. Accordingly, the chief current fiber usages of North American, indeed of European hemp, are non-textile.
Cannabinoids are divided into three groups. The first are naturally occurring 21-carbon terpenophenolic compounds found to date solely in plants of the Cannabis genus, currently termed phytocannabinoids (Pate 1994). The best known analgesic of these is Δ9-tetrahydrocannabinol (henceforth, THC)(Figure 1), first isolated and synthesized in 1964 (Gaoni and Mechoulam 1964). In plant preparations and whole extracts, its activity is complemented by other “minor” phytocannabinoids such as cannabidiol (CBD) (Figure 1), cannabis terpenoids and flavonoids, as will be discussed subsequently.